NTHI · Neonc Technologies Holdings, Inc.
$2.79
+0.07 (+2.57%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company's ability to continue as a going concern one year from the issuance date of this Form 10-Q. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company is actively taking steps to mitigate the substantial doubt about the Company's ability to continue as a going concern, including pursuing additional financing.”View the 10-Q filed Aug 10, 2026
Market Cap
$70.55M
Shares
25.94M
Volume · Oct 20
66.77K
Avg daily vol (3M)
195.36K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.72
Open$2.74
Day$2.69–2.90
52W close$2.53–11.83
Avg vol 30d193K
Short int758K · 2.9% float · 3.9d
Short vol70%
Last earningsAug 12, 2026
DataMar 2025–Oct 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 2 wks
filed Aug 10, 2026
call held Nov 12, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$47.20M
Trailing 12 months
Revenue growth YoY
-51.8%
Year over year
Operating margin
-145,637.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.97M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+29.6%
Year over year · more shares
Price change (1Y)
-73.7%
Trailing year
Short interest
2.9%
Latest settlement · 3.9 days to cover
Quarterly results
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−53%
below
Price vs 50-day avg
−27%
below
RSI (14)
40
neutral
MACD trend
Positive
52-week position
2%
near low
Momentum
relative strength
1-month return
−18%
trailing
6-month return
−37%
trailing
YTD return
−67%
this year
Relative strength
−45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Flat
1 of 21 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$653.0K over 90 days · 25% sells
Short interest
Rising
2.92% of float · ▲ +45.1% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
21 holders — mid 1-yr range
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
−52%
Y/Y
EPS growth
−364%
Y/Y
Quant / Vol
risk profile
Volatility
112%
annualized · 1-yr
Max drawdown
−79%
past year
ATR
11.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−53%
Bearish
Price vs 50-day avg
−27%
Bearish
RSI (14)
40
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Flat
1 of 21 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$653.0K over 90 days · 25% sells
Short interest
Rising
2.92% of float · ▲ +45.1% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
21 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $3
Now $3 · 2%
Range high $12
vs 200-day avg -53%
vs 50-day avg -27%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP total operating expenses excluding stock-based compensation non-GAAP | $8,417,974 | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP total operating expenses $14,069,887
-$5,651,913 Non-cash stock-based compensation expense
= Non-GAAP total operating expenses excluding stock-based compensation $8,417,974
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NTHI
this stock
Neonc Technologies Holdings, Inc.
|
$70.55M | -67.1% | -51.8% | — | 2.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 15, 2026
- This year
- 38
NeOnc Technologies Holdings, Inc. appointed Ali Mohammad Ahmad Alabedin as a Class I director effective October 9, 2026, after Steven L. Giannotta, M.D., resigned; the Department of Health – Abu Dhabi also authorized IND for NEO212 and NEO100.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NTHI | -0.4% | -18.3% | -36.9% | -20.1% | -67.1% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +1.1% | -17.4% | -44.6% | -20.6% | -79.5% |